Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences
‚Äč
Director
Telephone: 412-586-9771

UPMC Media Relations

UPMC Cardiologists Using New Drug-Eluting Stent Recently FDA Approved

PITTSBURGH, April 30, 2003 Physicians at the University of Pittsburgh Medical Centers Cardiovascular Institute have begun using a new drug-eluting stent to prevent reblockage of arteries following angioplasty.

Called the CYPHER Sirolimus-eluting Stent, it is the first drug-eluting stent to receive marketing approval from the Food and Drug Administration (FDA) for the treatment of blocked coronary arteries.

The new stent, which is approved for the treatment of previously untreated coronary artery lesions, was developed to address the problem of in-stent reblockage, or restenosis, which occurs in as many as 15 to 30 percent of patients who receive a bare metal stent. The stent is coated with the drug sirolimus, which is slowly released into the intima, or vessel lining, to prevent scar tissue growth through the openings in the stent mesh, which frequently leads to restenosis.

The stent provides new hope for patients with challenging case histories, stated Conrad Smith, M.D., interim chief of the division of cardiology at the University of Pittsburgh Medical Center. We are pleased to provide this advanced stent therapy in our community and to be one of the first hospitals in the United States to offer this effective treatment to patients.

Results of large-scale studies involving nearly 1,400 patients worldwide show that the stent, manufactured by Cordis Corporation, a Johnson & Johnson company, reduces the incidence of restenosis by more than 90 percent over a bare metal stent.

UPMC is committed to bringing patients innovative new technologies that have a positive effect on end results, said Dr. Smith.

©  UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences
Supplemental content provided by A.D.A.M. Health Solutions. All rights reserved.

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

For UPMC Mercy Patients: As a Catholic hospital, UPMC Mercy abides by the Ethical and Religious Directives for Catholic Health Care Services, as determined by the United States Conference of Catholic Bishops. As such, UPMC Mercy neither endorses nor provides medical practices and/or procedures that contradict the moral teachings of the Roman Catholic Church.

© UPMC
Pittsburgh, PA, USA UPMC.com